K.J. Harrison & Partners’s Briacell Therapeutics BCTX Stock Holding History

K.J. Harrison & Partners’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-580	Closed	-$249K	–	190
2024 Q1	$249K	Buy	580 +42	+8%	+$23.2K	0.04%	188
2023 Q4	$476K	Buy	538 +97	+22%	+$69.6K	0.08%	163
2023 Q3	$411K	Buy	441 +210	+91%	+$206K	0.09%	110
2023 Q2	$217K	Sell	231 -475	-67%	-$469K	0.04%	197
2023 Q1	$785K	Sell	706 -2,145	-75%	-$2.22M	0.16%	136
2022 Q4	$2.52M	Sell	2,851 -348	-11%	-$295K	0.49%	68
2022 Q3	$2.75M	Sell	3,199 -7,515	-70%	-$7.54M	0.97%	27
2022 Q2	$9.19M	Buy	10,714 +1,702	+19%	+$1.68M	2.48%	6
2022 Q1	$13.7M	Buy	+9,012	New	+$10.7M	2.21%	8

Other funds holding BCTX

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

OBWG

Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return

STA

Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

K.J. Harrison & Partners's BCTX Position: Q2 2024 in Review

K.J. Harrison & Partners sold out of Briacell Therapeutics (BCTX) in Q2 2024, closing a stake of 580 shares — an estimated $249K sold.

K.J. Harrison & Partners first reported a position in BCTX in Q1 2022 and held it in 9 quarters. The position peaked at $13.7M in Q1 2022. 20 funds tracked by Wall St. Rank hold BCTX as of Q2 2024.

K.J. Harrison & Partners reported no remaining Briacell Therapeutics position as of Q2 2024 after selling out during the quarter.
K.J. Harrison & Partners sold 580 Briacell Therapeutics shares in Q2 2024, an estimated $249K.
K.J. Harrison & Partners first reported a position in Briacell Therapeutics in Q1 2022 and held it in 9 quarters.
K.J. Harrison & Partners's Briacell Therapeutics position peaked at $13.7M in Q1 2022.
20 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2024.

Based on K.J. Harrison & Partners's 13F filing for Q2 2024, filed 26 Jul 2024.